Promiscuous receptors

Credit: Alfred Pasieka / Photo Researchers, Inc." /> Credit: Alfred Pasieka / Photo Researchers, Inc. The paper: R.B. Jones et al., "A quantitative protein interaction network for the ErbB receptors using protein microarrays," Nature, 439:168–74, 2006. (Cited in 98 papers) The finding: Gavin MacBeath's team at Harvard University wanted to find the proteins that get recruited to receptors in the first step of epidermal growth factor

Written byAndrea Gawrylewski
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

R.B. Jones et al., "A quantitative protein interaction network for the ErbB receptors using protein microarrays," Nature, 439:168–74, 2006. (Cited in 98 papers)

Gavin MacBeath's team at Harvard University wanted to find the proteins that get recruited to receptors in the first step of epidermal growth factor signaling. Using microarrays to perform a genome-wide assessment of the receptor network, they found that EGFR and ErbB2 bind to proteins more promiscuously, and activate many more signaling pathways, as they are overexpressed.

This paper enforced previous observations that overexpression of the EGFR and ErbB2 receptors are associated with human cancers; these receptors may turn on different signaling pathways that could alter the state of the cell, in some cases leading to uncontrollable cell division.

MacBeath said his group has found in follow-up work that their data can predict the differences in downstream signaling that occur with changes in the expression of other ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies